Healthcare - Biotechnology - NASDAQ - US
$ 56.62
-6.18 %
$ 2.29 B
Market Cap
-10.85
P/E
BALANCE SHEET
370 M
ASSETS
37.8 M
LIABILITIES
332 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Keros Therapeutics, Inc.
| Current Assets | 347 M |
| Cash & Short-Term Investments | 331 M |
| Receivables | 1.09 M |
| Other Current Assets | 15.1 M |
| Non-Current Assets | 22.7 M |
| Long-Term Investments | 1.21 M |
| PP&E | 19.5 M |
| Other Non-Current Assets | 2.05 M |
| Current Liabilities | 24.4 M |
| Accounts Payable | 5.45 M |
| Short-Term Debt | 1 M |
| Other Current Liabilities | 17.9 M |
| Non-Current Liabilities | 13.4 M |
| Long-Term Debt | 13.4 M |
| Other Non-Current Liabilities | 0 |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Cash & Cash Equivalents | 331.1 | 279.0 | 230.0 | 265.9 | 7.0 | 23.3 |
| Short Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.1 | 0.8 | 18.0 | 0.2 | 0.9 | 0 |
| Inventory | 0 | (0.8) | 3.1 | 1.5 | 0.8 | 0 |
| Other Current Assets | 15.1 | 5.9 | 3.2 | 1.6 | 1.0 | 2.3 |
| Total Current Assets | 347.3 | 285.8 | 251.4 | 267.7 | 8.9 | 25.5 |
| PP&E | 19.5 | 17.6 | 2.4 | 1.6 | 1.9 | 1.4 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 1.2 | 1.3 | 1.3 | 0.1 | 0.1 | 0.5 |
| Other Long Term Assets | 2.1 | 2.1 | 82 K | 0 | 0 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 370.0 | 306.8 | 255.3 | 269.4 | 11.0 | 27.4 |
| LIABILITIES | ||||||
| Accounts Payable | 5.5 | 3.3 | 3.6 | 2.1 | 2.1 | 0.5 |
| Short Term Debt | 1.0 | 0.9 | 1.7 | 0.8 | 0.4 | 0.2 |
| Other Current Liabilities | 17.9 | 12.2 | 6.4 | 4.0 | 2.0 | 0.5 |
| Total Current Liabilities | 24.4 | 16.5 | 11.8 | 7.2 | 4.5 | 11.5 |
| Long Term Debt | 13.4 | 25.6 | 0.5 | 1.0 | 0.9 | 0.6 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | (12.8) | (0.2) | (0.4) | 5.1 | 2.6 |
| Total Liabilities | 37.8 | 29.4 | 12.1 | 7.7 | 5.5 | 14.7 |
| EQUITY | ||||||
| Common Stock | 3 K | 2 K | 2 K | 2 K | 2 K | 1 K |
| Retained Earnings | (381.4) | (228.4) | (123.8) | (65.0) | (19.6) | (7.3) |
| Other Accumulative Comprehensive Income/Loss | 0 | 0 | 0 | (269.4) | (19.9) | (0.2) |
| Total Equity | 332.2 | 277.4 | 243.2 | 261.7 | 5.5 | 12.8 |
| Total Liabilities and Equity | 370.0 | 306.8 | 255.3 | 269.4 | 11.0 | 27.4 |
| SHARES OUTSTANDING | ||||||
| Common Shares Outstanding | 29.4 | 25.2 | 23.3 | 15.5 | 8.9 | 8.9 |